

Peter van der Meer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7039683/publications.pdf>

Version: 2024-02-01

249
papers

34,269
citations

13865

67
h-index

3732

179
g-index

253
all docs

253
docs citations

253
times ranked

33483
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 2129-2200.	2.2	13,008
2	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 891-975.	7.1	5,272
3	Anemia and Mortality in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2008, 52, 818-827.	2.8	601
4	Iron deficiency in chronic heart failure: An international pooled analysis. <i>American Heart Journal</i> , 2013, 165, 575-582.e3.	2.7	532
5	Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. <i>Annals of Medicine</i> , 2011, 43, 60-68.	3.8	506
6	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet</i> , 2020, 396, 1895-1904.	13.7	425
7	Treating oxidative stress in heart failure: past, present and future. <i>European Journal of Heart Failure</i> , 2019, 21, 425-435.	7.1	407
8	Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. <i>Clinical Research in Cardiology</i> , 2010, 99, 323-328.	3.3	393
9	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2017, 136, 1374-1383.	1.6	289
10	Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, 2565-2573.	2.2	274
11	Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. <i>Nature Genetics</i> , 2016, 48, 1151-1161.	21.4	261
12	MicroRNAs in heart failure: from biomarker to target for therapy. <i>European Journal of Heart Failure</i> , 2016, 18, 457-468.	7.1	235
13	Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2005, 46, 125-133.	2.8	232
14	Heart Failure Stimulates Tumor Growth by Circulating Factors. <i>Circulation</i> , 2018, 138, 678-691.	1.6	229
15	Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. <i>European Journal of Heart Failure</i> , 2018, 20, 910-919.	7.1	225
16	Red blood cell distribution width and 1-year mortality in acute heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 129-136.	7.1	224
17	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 827-843.	7.1	223
18	Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. <i>European Heart Journal</i> , 2007, 28, 2018-2027.	2.2	210

#	ARTICLE	IF	CITATIONS
19	Generation of Functional Ventricular Heart Muscle from Mouse Ventricular Progenitor Cells. <i>Science</i> , 2009, 326, 426-429.	12.6	202
20	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	2.8	199
21	Cardio-Oncology Services: rationale, organization, and implementation. <i>European Heart Journal</i> , 2019, 40, 1756-1763.	2.2	195
22	ACC/AHA Versus ESC Guidelines on Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2756-2768.	2.8	195
23	Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. <i>Nature Communications</i> , 2014, 5, 4926.	12.8	192
24	Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 44, 63-67.	2.8	178
25	A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 135-141.	2.6	176
26	The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 965-973.	7.1	172
27	Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2013, 102, 103-110.	3.3	171
28	Protective Effects of Erythropoietin in Cardiac Ischemia. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2161-2167.	2.8	167
29	Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	164
30	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM). <i>European Journal of Heart Failure</i> , 2017, 19, 1131-1141.	7.1	163
31	Signature of circulating microRNAs in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 414-423.	7.1	162
32	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2016, 18, 1096-1105.	7.1	160
33	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1973-1981.	2.8	159
34	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2165-2173.	2.2	159
35	Metabolic Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes by Inhibition of HIF1 α and LDHA. <i>Circulation Research</i> , 2018, 123, 1066-1079.	4.5	159
36	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet</i> , The, 2019, 394, 1254-1263.	13.7	159

#	ARTICLE	IF	CITATIONS
37	Timing of Erythropoietin Treatment for Cardioprotection in Ischemia/Reperfusion. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, 473-479.	1.9	152
38	Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. <i>International Journal of Cardiology</i> , 2014, 174, 268-275.	1.7	147
39	Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2018, 11, e004519.	3.9	147
40	Maintenance of serum potassium with sodium zirconium cyclosilicate (<sc>ZS</sc>â€œ) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1050-1056.	7.1	143
41	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 271, 132-139.	1.7	140
42	Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1303-1311.	7.1	138
43	Erythropoietin in cardiovascular diseases. <i>European Heart Journal</i> , 2004, 25, 285-291.	2.2	136
44	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 92-98.	4.1	129
45	Levels of Hematopoiesis Inhibitor <i>N</i>-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure. <i>Circulation</i> , 2005, 112, 1743-1747.	1.6	120
46	Cancer and heart disease: associations and relations. <i>European Journal of Heart Failure</i> , 2019, 21, 1515-1525.	7.1	120
47	Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. <i>Heart</i> , 2009, 95, 1309-1314.	2.9	115
48	A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 73-84.	4.1	115
49	Diuretic response in acute heart failureâ€”an analysis from ASCEND-HF. <i>American Heart Journal</i> , 2015, 170, 313-321.e4.	2.7	110
50	Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. <i>European Journal of Heart Failure</i> , 2018, 20, 951-962.	7.1	101
51	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020, 41, 3787-3797.	2.2	101
52	Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. <i>European Journal of Heart Failure</i> , 2004, 6, 853-859.	7.1	92
53	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. <i>European Journal of Heart Failure</i> , 2018, 20, 1664-1672.	7.1	92
54	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <sc>Translational Research Committee</sc> of the <sc>Heart Failure Association</sc> (<sc>HFA</sc>) of the <sc>European Society of Cardiology</sc> (<sc>ESC</sc>). <i>European Journal of Heart Failure</i> , 2020, 22, 2272-2289.	7.1	92

#	ARTICLE	IF	CITATIONS
55	Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals. <i>Nature Genetics</i> , 2020, 52, 1314-1332.	21.4	91
56	Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	89
57	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. <i>European Journal of Heart Failure</i> , 2017, 19, 1651-1660.	7.1	89
58	Incremental Prognostic Power of Novel Biomarkers (Growth-Differentiation Factor-15,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Td (Highly Sensitive Troponin T) in Patients With Advanced Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2013, 112, 831-837.	1.6	86
59	Waist-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1269-1277.	7.1	85
60	Selenium and outcome in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1415-1423.	7.1	84
61	Neurohormonal and clinical sex differences in heart failure. <i>European Heart Journal</i> , 2013, 34, 2538-2547.	2.2	83
62	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. <i>Molecular Psychiatry</i> , 2020, 25, 2392-2409.	7.9	83
63	The LifeLines Cohort Study: Prevalence and treatment of cardiovascular disease and risk factors. <i>International Journal of Cardiology</i> , 2017, 228, 495-500.	1.7	79
64	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 68-78.	7.1	79
65	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 507-517.	4.1	78
66	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. <i>Heart</i> , 2017, 103, 407-413.	2.9	74
67	Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. <i>European Heart Journal</i> , 2008, 29, 1510-1515.	2.2	72
68	Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. <i>European Journal of Heart Failure</i> , 2008, 10, 22-29.	7.1	72
69	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.	2.2	71
70	Hemoglobin levels and 30-day mortality in patients after myocardial infarction. <i>International Journal of Cardiology</i> , 2005, 100, 289-292.	1.7	70
71	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021, 23, 1040-1048.	7.1	70
72	Optimizing clinical use of biomarkers in high-risk acute heart failure patients. <i>European Journal of Heart Failure</i> , 2016, 18, 269-280.	7.1	69

#	ARTICLE	IF	CITATIONS
73	Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. <i>European Heart Journal</i> , 2019, 40, 3616-3625.	2.2	69
74	What have we learned about heart failure with mid-range ejection fraction one year after its introduction?. <i>European Journal of Heart Failure</i> , 2017, 19, 1569-1573.	7.1	67
75	Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. <i>Clinical Research in Cardiology</i> , 2017, 106, 598-609.	3.3	66
76	Anemia in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 201-208.	4.1	65
77	Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 457-462.	3.9	60
78	Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population. <i>European Journal of Heart Failure</i> , 2018, 20, 1205-1214.	7.1	60
79	The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences. <i>European Journal of Heart Failure</i> , 2014, 16, 655-662.	7.1	59
80	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2018, 20, 923-930.	7.1	57
81	Endogenous Erythropoietin and Outcome in Heart Failure. <i>Circulation</i> , 2010, 121, 245-251.	1.6	56
82	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 84-90.	1.7	55
83	Clinical importance of urinary sodium excretion in acute heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1438-1447.	7.1	55
84	Integrated Analysis of Contractile Kinetics, Force Generation, and Electrical Activity in Single Human Stem Cell-Derived Cardiomyocytes. <i>Stem Cell Reports</i> , 2015, 5, 1226-1238.	4.8	54
85	Iron deficiency and red cell indices in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 114-122.	7.1	54
86	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 231-239.	1.7	53
87	Red-light-sensitive BODIPY photoprotecting groups for amines and their biological application in controlling heart rhythm. <i>Chemical Communications</i> , 2020, 56, 5480-5483.	4.1	53
88	Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population. <i>Journal of the American Heart Association</i> , 2021, 10, e018549.	3.7	51
89	Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. <i>European Journal of Heart Failure</i> , 2017, 19, 116-125.	7.1	50
90	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1147-1155.	7.1	50

#	ARTICLE	IF	CITATIONS
91	Modeling Human Cardiac Hypertrophy in Stem Cell-Derived Cardiomyocytes. <i>Stem Cell Reports</i> , 2018, 10, 794-807.	4.8	49
92	Co-morbidities in heart failure. <i>Heart Failure Reviews</i> , 2014, 19, 163-172.	3.9	48
93	New Blood Pressure-Associated Loci Identified in Meta-Analyses of 475,000 Individuals. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	48
94	Dynamic loading of human engineered heart tissue enhances contractile function and drives a desmosome-linked disease phenotype. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	48
95	Exome-chip meta-analysis identifies novel loci associated with cardiac conduction, including ADAMTS6. <i>Genome Biology</i> , 2018, 19, 87.	8.8	47
96	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	2.2	47
97	High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. <i>European Journal of Heart Failure</i> , 2021, 23, 919-932.	7.1	46
98	Comorbidities in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 35-66.	1.8	45
99	Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology. <i>Journal of Clinical Medicine</i> , 2022, 11, 125.	2.4	45
100	Novel endotypes in heart failure: effects on guideline-directed medical therapy. <i>European Heart Journal</i> , 2018, 39, 4269-4276.	2.2	44
101	Functional Differences in Engineered Myocardium from Embryonic Stem Cell-Derived versus Neonatal Cardiomyocytes. <i>Stem Cell Reports</i> , 2013, 1, 387-396.	4.8	43
102	Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2019, 4, 696.	6.1	43
103	Prognostic value of N-terminal pro B-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 958-966.	7.1	42
104	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 243, 360-366.	1.7	42
105	Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1651-1658.	7.1	42
106	A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity. <i>European Heart Journal</i> , 2022, 43, 4496-4511.	2.2	41
107	Concise Review: Engineering Myocardial Tissue: The Convergence of Stem Cells Biology and Tissue Engineering Technology. <i>Stem Cells</i> , 2013, 31, 2587-2598.	3.2	40
108	Selenium, Selenoproteins, and Heart Failure: Current Knowledge and Future Perspective. <i>Current Heart Failure Reports</i> , 2021, 18, 122-131.	3.3	40

#	ARTICLE	IF	CITATIONS
109	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq1 1 0.784314 rgBT/Overlo	1.6	39
110	Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. European Heart Journal, 2019, 40, 1287-1293.	2.2	39
111	Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates. PLoS ONE, 2015, 10, e0125215.	2.5	38
112	Iron deficiency, anemia, and mortality in renal transplant recipients. Transplant International, 2016, 29, 1176-1183.	1.6	38
113	Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community. European Journal of Heart Failure, 2017, 19, 348-356.	7.1	38
114	OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction. Cardiovascular Research, 2018, 114, 1871-1882.	3.8	38
115	The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy. Scientific Reports, 2020, 10, 9819.	3.3	38
116	Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. Expert Opinion on Investigational Drugs, 2016, 25, 117-127.	4.1	37
117	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	7.1	37
118	Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. Science Translational Medicine, 2017, 9, .	12.4	36
119	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	35
120	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. International Journal of Cardiology, 2016, 203, 564-569.	1.7	35
121	Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease. BMC Nephrology, 2018, 19, 225.	1.8	35
122	Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO ₂ Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension. Journal of Cardiac Failure, 2017, 23, 777-782.	1.7	34
123	Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. European Journal of Preventive Cardiology, 2021, 28, 611-621.	1.8	33
124	Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. European Journal of Heart Failure, 2016, 18, 641-649.	7.1	32
125	Patiromer for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. European Journal of Heart Failure, 2022, 24, 230-238.	7.1	32
126	Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clinical Research in Cardiology, 2017, 106, 802-812.	3.3	30

#	ARTICLE	IF	CITATIONS
127	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 231-239.	1.7	30
128	Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls. <i>European Journal of Heart Failure</i> , 2020, 22, 1239-1246.	7.1	30
129	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2022, 118, 3016-3051.	3.8	30
130	Discovery of novel heart rate-associated loci using the Exome Chip. <i>Human Molecular Genetics</i> , 2017, 26, 2346-2363.	2.9	29
131	Long-term outcome of cardiac function in a population-based cohort of breast cancer survivors: A cross-sectional study. <i>European Journal of Cancer</i> , 2017, 81, 56-65.	2.8	29
132	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020, 109, 331-338.	3.3	28
133	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2022, 145, 87-89.	1.6	28
134	Concise Review: The Current State of Human In Vitro Cardiac Disease Modeling: A Focus on Gene Editing and Tissue Engineering. <i>Stem Cells Translational Medicine</i> , 2019, 8, 66-74.	3.3	27
135	Vitamin B12 and folate deficiency in chronic heart failure. <i>Heart</i> , 2015, 101, 302-310.	2.9	26
136	Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. <i>JACC: Heart Failure</i> , 2019, 7, 970-979.	4.1	26
137	Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algorithm in Acute Heart Failure (PUSH-AHF) trial. <i>European Journal of Heart Failure</i> , 2022, 24, 385-392.	7.1	26
138	Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years. <i>European Journal of Heart Failure</i> , 2020, 22, 338-346.	7.1	25
139	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2020, 8, 234-242.	4.1	25
140	Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure. <i>PLoS ONE</i> , 2017, 12, e0177242.	2.5	25
141	Anaemia and renal dysfunction in chronic heart failure. <i>Heart</i> , 2009, 95, 1808-1812.	2.9	24
142	Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 481-490.	4.7	24
143	The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. <i>European Journal of Heart Failure</i> , 2020, 22, 2102-2111.	7.1	24
144	Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy. <i>Nature Communications</i> , 2021, 12, 5180.	12.8	24

#	ARTICLE	IF	CITATIONS
145	Cardiomyopathy in patients with epidermolysis bullosa simplex with mutations in <i>KLHL24</i> . <i>British Journal of Dermatology</i> , 2018, 179, 1181-1183.	1.5	23
146	Hyperkalaemia: aetiology, epidemiology, and clinical significance. <i>European Heart Journal Supplements</i> , 2019, 21, A6-A11.	0.1	23
147	Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?. <i>Journal of Internal Medicine</i> , 2022, 291, 713-731.	6.0	23
148	Inflammation and anaemia in a broad spectrum of patients with heart failure. <i>Heart</i> , 2012, 98, 1237-1241.	2.9	22
149	Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. <i>American Journal of Cardiology</i> , 2018, 121, 107-112.	1.6	22
150	Cardiac Function After Radiation Therapy for Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 392-400.	0.8	22
151	Gain-of-function mutation in ubiquitin ligase KLHL24 causes desmin degradation and dilatation in hiPSC-derived engineered heart tissues. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	22
152	A Novel Approach to Drug Development in Heart Failure: Towards Personalized Medicine. <i>Canadian Journal of Cardiology</i> , 2014, 30, 288-295.	1.7	21
153	Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2018, 5, 570-578.	3.1	21
154	Pathophysiology and risk factors of peripartum cardiomyopathy. <i>Nature Reviews Cardiology</i> , 2022, 19, 555-565.	13.7	21
155	In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles. <i>Cardiovascular Research</i> , 2020, 116, 1875-1886.	3.8	20
156	Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart. <i>Journal of Internal Medicine</i> , 2020, 288, 491-506.	6.0	20
157	Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues. <i>Current Oncology Reports</i> , 2020, 22, 67.	4.0	20
158	Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 2058-2069.	7.1	20
159	Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2022, 24, 192-204.	7.1	20
160	Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study. <i>European Journal of Heart Failure</i> , 2018, 20, 474-480.	7.1	19
161	High selenium levels associate with reduced risk of mortality and new-onset heart failure: data from PREVENT. <i>European Journal of Heart Failure</i> , 2022, 24, 299-307.	7.1	19
162	Hemoglobin levels and new-onset heart failure in the community. <i>American Heart Journal</i> , 2015, 169, 94-101.e2.	2.7	18

#	ARTICLE	IF	CITATIONS
163	Electrocardiographic features and their echocardiographic correlates in peripartum cardiomyopathy: results from the ESC EORP PPCM registry. ESC Heart Failure, 2021, 8, 879-889.	3.1	18
164	Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the <sc>REPORTâ€HF</sc> registry. European Journal of Heart Failure, 2022, 24, 645-652.	7.1	18
165	Validity and Predictive Value of a Portable Two-Channel Sleep-Screening Tool in the Identification of Sleep Apnea in Patients With Heart Failure. Journal of Cardiac Failure, 2015, 21, 848-855.	1.7	17
166	Prehospital risk stratification in patients with chest pain. Emergency Medicine Journal, 2021, 38, 814-819.	1.0	17
167	Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e008532.	3.9	17
168	Diastolic Dysfunction is Common in Survivors of Pediatric Differentiated Thyroid Carcinoma. Thyroid, 2017, 27, 1481-1489.	4.5	16
169	Active Smoking and Hematocrit and Fasting Circulating Erythropoietin Concentrations in the General Population. Mayo Clinic Proceedings, 2018, 93, 337-343.	3.0	16
170	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2019, 25, 866-874.	1.7	16
171	Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study. PLoS Medicine, 2019, 16, e1002818.	8.4	16
172	Genetic Determinants of Electrocardiographic P-Wave Duration and Relation to Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2020, 13, 387-395.	3.6	16
173	A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure. Nutrients, 2020, 12, 2541.	4.1	16
174	LC-MS analysis of key components of the glutathione cycle in tissues and body fluids from mice with myocardial infarction. Journal of Pharmaceutical and Biomedical Analysis, 2018, 160, 289-296.	2.8	15
175	Mitochondrial Function, Skeletal Muscle Metabolism, and Iron Deficiency in Heart Failure. Circulation, 2019, 139, 2399-2402.	1.6	15
176	Genetic risk and atrial fibrillation in patients with heart failure. European Journal of Heart Failure, 2020, 22, 519-527.	7.1	15
177	Erythropoietin: Repair of the Failing Heart**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. Journal of the American College of Cardiology, 2006, 48, 185-186.	2.8	14
178	Erythropoietin and heart failure: the end of a promise?. European Journal of Heart Failure, 2013, 15, 479-481.	7.1	13
179	High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. European Journal of Heart Failure, 2016, 18, 814-821.	7.1	13
180	Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure). Circulation: Heart Failure, 2018, 11, e004431.	3.9	13

#	ARTICLE	IF	CITATIONS
181	Impact of sex-specific target dose in chronic heart failure patients with reduced ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 957-965.	1.8	13
182	Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2458-2466.	3.1	13
183	Selenoprotein DIO2 Is a Regulator of Mitochondrial Function, Morphology and UPRmt in Human Cardiomyocytes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11906.	4.1	13
184	Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 433-439.	2.6	12
185	Rationale and Design of the Groningen Intervention Study for the Preservation of Cardiac Function with Sodium Thiosulfate after St-segment Elevation Myocardial Infarction (GIPS-IV) trial. <i>American Heart Journal</i> , 2022, 243, 167-176.	2.7	12
186	Iron deficiency in heart failure—time to redefine. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1647-1649.	1.8	12
187	Acute heart failure in the young: Clinical characteristics and biomarker profiles. <i>International Journal of Cardiology</i> , 2016, 221, 1067-1072.	1.7	11
188	Cardiotoxicity of breast cancer treatment: no easy solution for an important long-term problem. <i>European Heart Journal</i> , 2016, 37, 1681-1683.	2.2	11
189	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	11
190	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. <i>European Journal of Heart Failure</i> , 2021, 23, 1677-1686.	7.1	11
191	Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIostat-CHF. <i>Cardiovascular Research</i> , 2022, 118, 1964-1977.	3.8	10
192	ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca ²⁺ Handling and Promotes Pathological Cardiac Hypertrophy through CaMKII β . <i>International Journal of Molecular Sciences</i> , 2021, 22, 4427.	4.1	9
193	Erythropoietin: From Hematopoiesis to Cardioprotection. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 7-8.	2.6	8
194	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 281-293.	2.6	8
195	N-terminal pro-B-type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure. <i>ESC Heart Failure</i> , 2018, 5, 279-287.	3.1	8
196	Human iPSC-Derived Cardiomyocytes of Peripartum Patients With Cardiomyopathy Reveal Aberrant Regulation of Lipid Metabolism. <i>Circulation</i> , 2020, 142, 2288-2291.	1.6	8
197	Immune checkpoint inhibitor-associated myocarditis. <i>Netherlands Heart Journal</i> , 2022, 30, 295-301.	0.8	8
198	Residual confounding in observational studies: new data from the old DIG trial. <i>European Heart Journal</i> , 2019, 40, 3342-3344.	2.2	7

#	ARTICLE	IF	CITATIONS
199	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 808-811.	1.7	7
200	Clinical implications of low estimated protein intake in patients with heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, , .	7.3	7
201	Erythropoietin in cardiovascular diseases: exploring new avenues. <i>Clinical Science</i> , 2008, 114, 289-291.	4.3	6
202	Asialoerythropoietin to Protect the Failing Heart. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1959-1960.	2.8	6
203	The unfulfilled promise of erythropoietin in patients with MI. <i>Nature Reviews Cardiology</i> , 2011, 8, 425-426.	13.7	6
204	Peripartum cardiomyopathy: Euro Observational Research Program. <i>Netherlands Heart Journal</i> , 2014, 22, 396-400.	0.8	6
205	Value of digoxin in patients with heart failure: new pieces to the puzzle. <i>European Journal of Heart Failure</i> , 2018, 20, 1146-1147.	7.1	6
206	Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy. <i>Familial Cancer</i> , 2019, 18, 19-27.	1.9	6
207	Anemia and erythropoietin in heart failure. <i>Heart Failure Monitor</i> , 2008, 6, 28-33.	0.7	6
208	A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin?. <i>European Heart Journal</i> , 2022, 43, 2221-2223.	2.2	6
209	Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14del. <i>Current Heart Failure Reports</i> , 2022, 19, 170-179.	3.3	6
210	Stem cells in heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 642-644.	7.1	5
211	Erythropoietin, iron, or both in heart failure: FAIRâ€œHF in perspective. <i>European Journal of Heart Failure</i> , 2010, 12, 104-105.	7.1	5
212	Erythropoiesis-Stimulating Agents and Heart Failure. <i>Cardiovascular Therapeutics</i> , 2011, 29, e52-e59.	2.5	5
213	Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: A meta-analysis of individual patient data. <i>American Heart Journal</i> , 2014, 168, 354-362.e2.	2.7	5
214	Associations between volume status and circulating microRNAs in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1077-1078.	7.1	5
215	Active smoking and macrocytosis in the general population: Two populationâ€œbased cohort studies. <i>American Journal of Hematology</i> , 2019, 94, E45-E48.	4.1	5
216	Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction. <i>Netherlands Heart Journal</i> , 2021, 29, 383-393.	0.8	5

#	ARTICLE	IF	CITATIONS
217	Pathophysiological pathways in patients with heart failure and atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2478-2487.	3.8	5
218	Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2427.	4.1	5
219	Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?. <i>Journal of Clinical Medicine</i> , 2022, 11, 2976.	2.4	5
220	Cardiac regeneration in left ventricular dysfunction: are we asking the right questions?. <i>European Journal of Heart Failure</i> , 2012, 14, 1-4.	7.1	4
221	Sleep-disordered breathing and chronic heart failure: changing position may be important. <i>European Journal of Heart Failure</i> , 2015, 17, 1219-1222.	7.1	4
222	Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , 2020, 22, 751-754.	7.1	4
223	Sleep-disordered Breathing in Heart Failure – Current State of the Art. <i>Cardiac Failure Review</i> , 2015, 1, 16.	3.0	4
224	Keratin 14 Degradation and Aging in Epidermolysis Bullosa Simplex due to KLHL24 Gain-of-Function Variants. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2271-2274.e6.	0.7	4
225	Heart failure highlights in 2011. <i>European Journal of Heart Failure</i> , 2012, 14, 1090-1096.	7.1	3
226	Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1527-1538.	1.8	3
227	Single-Cell Functional Analysis of Stem-Cell Derived Cardiomyocytes on Micropatterned Flexible Substrates. <i>Current Protocols in Stem Cell Biology</i> , 2017, 43, 1F.20.1-1F.20.9.	3.0	3
228	Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 903-906.	7.1	3
229	Functional investigation of two simultaneous or separately segregating <i>DSP</i> variants within a single family supports the theory of a dose-dependent disease severity. <i>Experimental Dermatology</i> , 2022, , .	2.9	3
230	Anemia is associated with an increased central venous pressure and mortality in a broad spectrum of cardiovascular patients. <i>Clinical Research in Cardiology</i> , 2014, 103, 467-476.	3.3	2
231	Meta-GWAS and Meta-Analysis of Exome Array Studies Do Not Reveal Genetic Determinants of Serum Hcpidin. <i>PLoS ONE</i> , 2016, 11, e0166628.	2.5	2
232	Genetically Determined High Levels of Iron Parameters Are Protective for Coronary Artery Disease. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002544.	3.6	2
233	Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 1049-1052.	7.1	2
234	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?. <i>Cardiac Failure Review</i> , 2020, 6, e21.	3.0	2

#	ARTICLE	IF	CITATIONS
235	Response: A Portable Device as Sleep-Screening Tool in the Identification of Obstructive Sleep Apnea in Chronic Heart Failure: Which Value Should We Consider as Cutoff?. <i>Journal of Cardiac Failure</i> , 2016, 22, 168.	1.7	1
236	FC 021EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	1
237	Efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency with and without anaemia: a subgroup analysis of AFFIRM-AHF. <i>European Heart Journal</i> , 2021, 42, .	2.2	1
238	Fluctuating iron levels in heart failure: when and where to look at?. <i>European Journal of Heart Failure</i> , 2022, 24, 818-820.	7.1	1
239	Response to Letter Regarding Article, "Endogenous Erythropoietin and Outcome in Heart Failure". <i>Circulation</i> , 2010, 122, .	1.6	0
240	Neuromodulation for systolic heart failure: more than a placebo effect?. <i>European Journal of Heart Failure</i> , 2017, 19, 401-403.	7.1	0
241	Predicting heart failure: one size does not fit all. <i>European Journal of Heart Failure</i> , 2018, 20, 674-676.	7.1	0
242	FP387IRON DEFICIENCY, ERYTHROPOIETIN, AND FIBROBLAST GROWTH FACTOR 23 IN THE GENERAL POPULATION. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i164-i164.	0.7	0
243	5223Absolute and functional iron deficiency in heart failure defined and described. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
244	2371Electrocardiographic features and their echocardiographic correlates in peripartum cardiomyopathy based on the EURObservational registry on PPCM. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
245	P566Activated amyloid-beta pathways in patients with atrial fibrillation and heart failure, a pathway analysis in BIOSTAT. <i>Europace</i> , 2020, 22, .	1.7	0
246	Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients? Reply. <i>European Journal of Heart Failure</i> , 2020, 22, 1933-1934.	7.1	0
247	Effect of a tailored exercise intervention during or after chemotherapy on cardiovascular morbidity in cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12018-12018.	1.6	0
248	An Erythropoietin-Independent Mechanism of Erythrocytic Precursor Proliferation Underlies Hypoxia Tolerance in Sea Nomads. <i>Frontiers in Physiology</i> , 2021, 12, 760851.	2.8	0
249	Selenium deficiency is associated with new-onset atrial fibrillation in PREVEND: a prospective general population cohort. <i>European Journal of Preventive Cardiology</i> , 2022, 29, .	1.8	0